The general public did not know much about mRNA vaccines a few months ago; now biotech firms like Moderna, BioNTech or CureVac have almost become household brand-names! We spoke this month with Sander Slootweg, Founder and Managing Partner of Forbion – one of the leading biotech investors in Europe. He told us about the incredible breakthrough life sciences have made in the last decades, how the European biotech ecosystem is reaching new milestones and why LPs are increasingly interested in this space.

Enjoy this May IPEM rendez-vous!

Table of content

  • Chapter 1: Introduction
  • Chapter 2 (00.28): Even for a life science expert, the vaccine discovery and rollout have been surprisingly fast!
  • Chapter 3 (1:10): The European biotech industry really led this success
  • Chapter 4 (2:06): Historically European biotech investors have developed a frugal approach that is now paying out
  • Chapter 5 (2:59): and this is quite different from the US approach…
  • Chapter 6 (3:53): The Forbion recipe?
  • Chapter 7 (5:30): What it take to make a successful biotech investor?
  • Chapter 8 (6:33): Life science is also getting the attention of generalist players…
  • Chapter 9 (7:47): The growing appetite of LPs for life sciences
  • Chapter 10 (8:53): The convergence of biotech and AI is the next frontier

A special thank you to Sander Slootweg, Co-Founder & Managing Partner of Forbion, for sharing with us his thoughts!

And stay tuned for the next IPEM RDV!

Become part of the IPEM Community

We help foster and engage the Private Capital community internationally through our live and digital events. Join thousands of your peers and enjoy new connections!

Follow us

IPEM: Follow us on YoutubeIPEM: Follow us on Linkedin

News